Hyperprolactinemia caused by risperidone. Hyperprolactinemia
Conditions
Interventions
Intervention 1: Intervention group:The group treated with immediate-release oral metformin 500 mg, prepared by the pharmaceutical group, with a starting dose of 1/2 tablet twice a day, which was incre
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
10 Years to 18 Years
Inclusion criteria
Inclusion criteria: Patient and parent consent to participate in the study Age 10 to 18 years Psychiatric necessity for taking risperidone Normal prolactin at the beginning of the study
Exclusion criteria
Exclusion criteria: Allergy to risperidone or metformin Need to change risperidone or add a second drug due to lack of control of psychiatric symptoms Intolerable or severe side effects with risperidone and metformin Occurrence of short-term physical symptoms of hyperprolactinemia Previous or current history of neurological disease (current seizure disorders, history of head trauma, migraine) Previous or current history of systemic disease (blood, endocrine, liver, thyroid, kidney, metabolic disease) Smoking and any type of drug Taking medication that interacts with metformin Positive pregnancy test in teenage girls Taking any type of drug affecting the plasma level of prolactin (including other antipsychotics, antidepressants, and stimulants)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prolactin blood level. Timepoint: before the start of the intervention and 6 weeks after the start of the drug. Method of measurement: Blood prolactin level check. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMina Ayatollahi Mehrjardi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed